福瑞达: 鲁商福瑞达医药股份有限公司2025年半年度报告摘要

Core Points - The company reported a total asset of approximately 6.04 billion yuan, reflecting a slight increase of 0.61% compared to the previous year [1] - The operating revenue for the reporting period was approximately 1.79 billion yuan, showing a decrease of 7.05% year-on-year [1] - The total profit amounted to approximately 153.14 million yuan, which is a decline of 17.31% compared to the same period last year [1] - The net profit attributable to shareholders was approximately 0.11 yuan per share, down 15.38% from the previous year [1] Financial Summary - Total assets at the end of the reporting period were 6,037,060,817.19 yuan, compared to 6,000,330,923.23 yuan at the end of the previous year [1] - Operating revenue decreased from 1,925,374,405.82 yuan to 1,789,541,668.33 yuan [1] - Total profit decreased from 185,198,599.49 yuan to 153,143,384.43 yuan [1] - The net profit attributable to shareholders decreased from 0.13 yuan per share to 0.11 yuan per share [1] Shareholder Information - The largest shareholder, Shandong Commercial Group Co., Ltd., holds 51.62% of the shares, amounting to 524,739,200 shares [2] - Other significant shareholders include Shandong World Trade Center and LuShang Group Co., Ltd., holding 0.97% and 1.69% respectively [2] - The total number of shareholders at the end of the reporting period was 47,512 [1]